keyword
MENU ▼
Read by QxMD icon Read
search

Statins cancer

keyword
https://www.readbyqxmd.com/read/28524155/statin-use-candidate-mevalonate-pathway-biomarkers-and-colon-cancer-survival-in-a-population-based-cohort-study
#1
Ronan T Gray, Maurice B Loughrey, Peter Bankhead, Chris R Cardwell, Stephen McQuaid, Roisin F O'Neill, Kenneth Arthur, Victoria Bingham, Claire McGready, Anna T Gavin, Jacqueline A James, Peter W Hamilton, Manuel Salto-Tellez, Liam J Murray, Helen G Coleman
BACKGROUND: Statin use after colorectal cancer diagnosis may improve survival but evidence from observational studies is conflicting. The anti-cancer effect of statins may be restricted to certain molecular subgroups. In this population-based cohort study, the interaction between p53 and 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR) expression, KRAS mutations, and the association between statin use and colon cancer survival was assessed. METHODS: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008...
May 18, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28521870/the-use-of-statins-alone-or-in-combination-with-pioglitazone-and-other-drugs-for-the-treatment-of-non-alcoholic-fatty-liver-disease-non-alcoholic-steatohepatitis-and-related-cardiovascular-risk-an-expert-panel-statement
#2
REVIEW
Vasilios G Athyros, Theodore K Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S Ganotakis, John Goudevenos, Moses S Elisaf, Georgios Germanidis, Olga Giouleme, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Loukianos S Rallidis, Dimitrios Richter, Apostolos G Tsapas, Alexandros D Tselepis, Konstantinos Tsioufis, Konstantinos Tziomalos, Themistoklis Tzotzas, Themistoklis G Vasiliadis, Charalambos Vlachopoulos, Dimitri P Mikhailidis, Christos Mantzoros
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is characterized by accumulation of fat (>5% of the liver tissue), in the absence of alcohol abuse or other chronic liver diseases. It is closely related to the epidemic of obesity, metabolic syndrome or type 2 diabetes mellitus (T2DM). NAFLD can cause liver inflammation and progress to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular cancer (HCC). Nevertheless, cardiovascular disease (CVD) is the most common cause of death in NAFLD/NASH patients...
June 2017: Metabolism: Clinical and Experimental
https://www.readbyqxmd.com/read/28521491/hif-1%C3%AE-acts-as-a-molecular-target-for-simvastatin-cytotoxicity-in-b16-f10-melanoma-cells-cultured-under-chemically-induced-hypoxia
#3
Emilia Licarete, Alina Sesarman, Valentin Florian Rauca, Lavinia Luput, Laura Patras, Manuela Banciu
Our previous studies reported that one of the main mechanisms of the antitumor activity of simvastatin (SIM) in B16.F10 murine melanoma cells was associated with strong suppression of the constitutive cell production of the α subunit of the heterodimeric transcription factor hypoxia-inducible factor (HIF)-1. Thus, the present study aimed to broaden this finding under hypoxic conditions induced by incubation of B16.F10 cells with cobalt chloride, when the constitutive production of HIF-1α in these melanoma cells is amplified by inducible expression of this factor...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28520522/perceptions-of-statin-discontinuation-among-patients-with-life-limiting-illness
#4
Jennifer Tjia, Jean S Kutner, Christine S Ritchie, Patrick J Blatchford, Rachael E Bennett Kendrick, Maryjo Prince-Paul, Tamara J Somers, Mary Lynn McPherson, Jeff A Sloan, Amy P Abernethy, Jon P Furuno
BACKGROUND: Optimal management of chronic medications for patients with life-limiting illness is uncertain. Medication deprescribing may improve outcomes in this population, but patient concerns regarding deprescribing are unclear. OBJECTIVE: The aim of this study was to quantify the perceived benefits and concerns of statin discontinuation among patients with life-limiting illness. DESIGN: Baseline data from a multicenter, pragmatic clinical trial of statin discontinuation were used...
May 18, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28512021/statin-use-after-diagnosis-of-colon-cancer-and-patient-survival
#5
Philip W Voorneveld, Marlies S Reimers, Esther Bastiaannet, Rutger J Jacobs, Ronald van Eijk, Marjolein M J Zanders, Ron M C Herings, Myrthe P P van Herk-Sukel, Liudmila L Kodach, Tom van Wezel, Peter J K Kuppen, Hans Morreau, Cornelis J H van de Velde, James C H Hardwick, Gerrit Jan Liefers
BACKGROUND & AIMS: Statin use has been associated with a reduced incidence of colorectal cancer, and might also affect survival of patients diagnosed with colon cancer. Statins are believed to inhibit Ras signaling, and also activate the bone morphogenetic protein (BMP) signaling pathway in colorectal cancer cells. We investigated the effects of statins on overall survival of patients with a diagnosis of colon cancer, and whether their effects were associated with changes in KRAS or the BMP signaling pathways...
May 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28503146/statin-therapy-is-associated-with-reduced-risk-of-peptic-ulcer-disease-in-the-taiwanese-population
#6
Chun-Jung Lin, Wei-Chih Liao, Yu-An Chen, Hwai-Jeng Lin, Chun-Lung Feng, Cheng-Li Lin, Ying-Ju Lin, Min-Chuan Kao, Mei-Zi Huang, Chih-Ho Lai, Chia-Hung Kao
Although statin use may affect the severity of chronic gastritis and gastric cancer, no data exists about the relationship between statin therapy and risk of peptic ulcer disease (PUD) in patients. We investigated the effect of statin use and the incidence of PUD from the Taiwan National Health Insurance Research Database (NHIRD). A total of 35,194 patients records for medical claims were enrolled. We performed a population-based case-control analysis to compare the incidence of PUD in patients who were prescribed statins and that in patients who were not...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28495423/the-current-evidence-of-statin-use-affecting-glioblastoma-prognosis
#7
Victor M Lu, Kerrie L McDonald
Cholesterol-lowering statins have been postulated to improve cancer outcomes by many unconfirmed mechanisms. The prognosis of glioblastoma (GBM) remains dismal, and there is a paucity of evidence regarding the potential for preoperative statins to exert a benefit upon prognosis. In light of a recent report, the current evidence in the literature regarding statin use affecting GBM prognosis is discussed.
May 8, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28494529/nash-therapy-omega-3-supplementation-vitamin-e-insulin-sensitizers-and-statin-drugs
#8
Stephen Caldwell
Non-alcoholic steatohepatitis (NASH) is the more aggressive form of non-alcoholic fatty liver disease (NAFLD). NASH can progress to hepatic fibrosis, cirrhosis, portal hypertension and primary liver cancer. Therapy is evolving with a substantial number of trials of promising new agents now in progress. In this article however, we will examine data for several older forms of therapy which have been fairly extensively studied over the years: Polyunsaturated Fatty Acid (PUFA) supplements, vitamin E, insulin sensitizing agents with a focus on pioglitazone and statin agents...
May 10, 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28489569/statin-use-and-survival-outcomes-in-endocrine-related-gynecologic-cancers-a-systematic-review-and-meta-analysis
#9
Weimin Xie, Li Ning, Yuenan Huang, Yan Liu, Wen Zhang, Yingchao Hu, Jinghe Lang, Jiaxin Yang
Previous studies investigating the association between statin use and survival outcomes in gynecologic cancers have yielded controversial results. We conducted a systematic review and meta-analysis to evaluate the association based on available evidence. We searched the databases of the Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and PubMed from inception to January 2017. Studies that evaluated the association between statin use and survival outcomes in gynecologic cancers were included...
April 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28487295/statin-use-serum-lipids-and-prostate-inflammation-in-men-with-a-negative-prostate-biopsy-results-from-the-reduce-trial
#10
Emma H Allott, Lauren E Howard, Adriana C Vidal, Daniel M Moreira, Ramiro Castro-Santamaria, Gerald L Andriole, Stephen J Freedland
Statin use is associated with lower advanced prostate cancer risk. In addition to cholesterol lowering, statins have systemic anti-inflammatory properties. However, their effect on histologic prostate inflammation is not well understood, particularly among men at increased prostate cancer risk but with a negative prostate biopsy. We examined associations between serum lipid levels, statin use, and histologic prostate inflammation using data from 6,655 men with a negative baseline prostate biopsy in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial...
May 9, 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28486205/statin-use-after-esophageal-cancer-diagnosis-and-survival-a-population-based-cohort-study
#11
Chris R Cardwell, Andrew D Spence, Carmel M Hughes, Liam J Murray
BACKGROUND: A recent epidemiological study of esophageal cancer patients concluded statin use post-diagnosis was associated with large (38%) and significant reductions in cancer-specific mortality. We investigated statin use and cancer-specific mortality in a large population-based cohort of esophageal cancer patients. METHODS: Newly diagnosed [2009-2012] esophageal cancer patients were identified from the Scottish Cancer Registry and linked with the Prescribing Information System and Scotland Death Records (to January 2015)...
May 6, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28481295/inhibiting-hdac1-enhances-the-anti-cancer-effects-of-statins-through-downregulation-of-ggtase-i%C3%AE-expression
#12
Ran Li, Ye-Hua Gan
Hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors, namely statins, are potential anti-tumor agents. Previously, we showed that a pan-histone deacetylase (HDAC) inhibitor enhances the anti-tumor effects of the HMG-CoA inhibitor. However, the underlying mechanisms were not fully understood. Cancer cell lines (CAL-27 and SACC-83) were exposed to pan-HDAC inhibitor, or HDAC1 inhibitor, or geranylgeranyl transferase type I (GGTase-I) inhibitor alone or in combination with statin. Cell viability, apoptosis, migration, and invasion were assessed by Cell Count Kit-8, 4',6-diamidino-2-phenylindole staining, and transwell assay, respectively...
May 8, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28479040/statins-as-inhibitors-of-lung-cancer-bone-metastasis
#13
Devanand Sarkar
No abstract text is available yet for this article.
April 20, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28475851/do-statins-improve-survival-in-small-cell-lung-cancer
#14
Sanjay Popat
No abstract text is available yet for this article.
May 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28460629/effect-on-non-vascular-outcomes-of-lowering-ldl-cholesterol-in-patients-with-chronic-kidney-disease-results-from-the-study-of-heart-and-renal-protection
#15
C Reith, N Staplin, W G Herrington, W Stevens, J Emberson, R Haynes, M Mafham, J Armitage, A Cass, J C Craig, L Jiang, T Pedersen, C Baigent, M J Landray
BACKGROUND: Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of cancer or death from any non-vascular cause. However, non-randomized data have suggested that statin therapy may have effects (both adverse and beneficial) on particular non-vascular conditions that do not cause death. METHODS: The Study of Heart and Renal Protection (SHARP) randomized patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg (simvastatin/ezetimibe) daily versus matching placebo...
May 1, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28454732/fluvastatin-prevents-lung-adenocarcinoma-bone-metastasis-by-triggering-autophagy
#16
Zuozhang Yang, Zhenyi Su, Judy Park DeWitt, Lin Xie, Yongbin Chen, Xiaojuan Li, Lei Han, Dongqi Li, Junfeng Xia, Ya Zhang, Yihao Yang, Congguo Jin, Jing Zhang, Su Li, Kun Li, Zhiping Zhang, Xin Qu, Zewei He, Yanjin Chen, Yan Shen, Mingyan Ren, Zhongqin Yuan
Bone is one of the most preferred sites of metastasis in lung cancer. Currently, bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal-related events (SREs). However, both bisphosphonates and denosumab significantly increase the risk for jaw osteonecrosis. Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the most frequently prescribed cholesterol-lowering agents, have been reported to inhibit tumor progression and induce autophagy in cancer cells...
April 11, 2017: EBioMedicine
https://www.readbyqxmd.com/read/28454668/choosing-wisely-measuring-the-burden-of-medications-in-older-adults-near-the-end-of-life-nationwide-longitudinal-cohort-study
#17
Lucas Morin, Davide L Vetrano, Debora Rizzuto, Amaia Calderón-Larrañaga, Johan Fastbom, Kristina Johnell
BACKGROUND: The burden of medications near the end of life has recently come under scrutiny, because several studies suggested that people with life-limiting illness receive potentially futile treatments. METHODS: We identified 511,843 older adults (>65 years) who died in Sweden between 2007 and 2013 and reconstructed their drug prescription history for each of the last 12 months of life through the Swedish Prescribed Drug Register. Decedents' characteristics at time of death were assessed through record linkage with the National Patient Register, the Social Services Register, and the Swedish Education Register...
April 25, 2017: American Journal of Medicine
https://www.readbyqxmd.com/read/28454210/statins-and-pancreatic-cancer
#18
Jun Gong, Esha Sachdev, Lori A Robbins, Emily Lin, Andrew E Hendifar, Monica M Mita
Pancreatic cancer remains among the most lethal cancers, despite ongoing advances in treatment for all stages of the disease. Disease prevention represents another opportunity to improve patient outcome, with metabolic syndrome and its components, such as diabetes, obesity and dyslipidemia, having been recognized as modifiable risk factors for pancreatic cancer. In addition, statins have been shown to potentially reduce pancreatic cancer risk and to improve survival in patients with a combination of metabolic syndrome and pancreatic cancer...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28453187/pcsk9-monoclonal-antibodies-for-the-primary-and-secondary-prevention-of-cardiovascular-disease
#19
REVIEW
Amand F Schmidt, Lucy S Pearce, John T Wilkins, John P Overington, Aroon D Hingorani, Juan P Casas
BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially reducing CVD risk as well...
April 28, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28445391/telomerase-inhibitory-effects-of-red-pigment-rubropunctatin-and-statin-monacolin-l-isolated-from-red-yeast-rice
#20
Baojun Xu, Qijun Wang, Changkeun Sung
In addition to the cholesterol-lowering activity of red yeast rice (RYR), its anticancer activities have been frequently reported. However, the mechanism of action of the anticancer activity of RYR is not yet fully understood. The objective of the current study was to elucidate anticancer compositions and anticancer mechanism of actions of RYR. The isolated compounds from RYR were subjected to anti-proliferation assay, apoptosis assay via flow cytometry, and telomerase inhibitory assay via telomeric repeat amplification protocol-PCR (TRAP-PCR) assay, and Western blotting assay in an in vitro cell culture system...
April 26, 2017: Genes
keyword
keyword
7329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"